platlet rich plasma
Biologic
platlet rich plasma is one of 49 biologic programs targeting Carpal Tunnel Syndrome. It is currently in development.
2
Indications
5
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
66 competitors in Carpal Tunnel Syndrome
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Neurontin
VViatris Specialty LLC
Approved
N-Acetyl Cyteien
SStanford University
Approved
Celestone
SSchering-Plough
Phase 3
Epidiolex
Jazz PharmaceuticalsPhase 2
Xylocaine
AstraZenecaPhase 3
Acetyl-L-Carnitine
Mario Negri Institute for Pharmacological ResearchPhase 3
Theraworx
JJohn Fowler
Approved
Botox
RRevance Therapeutics, Inc.
Phase 2
Ibuprofen Arginine
UUniversidad Europea de Madrid
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Endometrial2 trials
Tendinopathy1 trial
The Effect of Multiple Injection of Platlet-rich Plasma in Chronic Patellar Tendinopathy
Unknown status·—·Phase 2/3·NCT03986372·60 enrolled
Pregnancy1 trial
the Effect of Hyaluronic Acid Intrauterine Wash on Endometrial Receptivity and Pregnancy Outcome
Recruiting·—·Phase 2·NCT06937645·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for platlet rich plasma. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company
- TTanta University